Syneos Health Completes Acquisition of Synteract
Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include, but are not limited to: reliance on key personnel; principal investigators and patients; general and international economic, political, and other risks, including currency and stock market fluctuations and the uncertain economic environment; any failure to realize the anticipated benefits of the acquisition of Synteract; risks related to the COVID-19 pandemic; the company's ability to adequately price its contracts and not overrun cost estimates; any adverse effects from the company's customer or therapeutic area concentration; the company's ability to maintain or generate new business awards; the company's ability to increase its market share, grow its business, and execute its growth strategies; the company's backlog not being indicative of future revenues and its ability to realize the anticipated future revenue reflected in its backlog; fluctuations in the company's operating results and effective income tax rate; risks related to the company's information systems and cybersecurity; changes and costs of compliance with regulations related to data privacy; risks related to the United Kingdom’s withdrawal from the European Union; risks related to the company's transfer pricing policies; failure to perform services in accordance with contractual requirements, regulatory requirements and ethical considerations; risks relating to litigation and government investigations; risks associated with the company's early phase clinical facilities; insurance risk; risks of liability resulting from harm to patients; success of investments in the company's customers’ business or drugs; foreign currency exchange rate fluctuations; risks associated with acquired businesses, including the ability to integrate acquired operations, products, and technologies in our business; risks related to the company's income tax expense and tax reform; risks relating to the company's intellectual property; risks associated with the company's acquisition strategy; failure to realize the full value of goodwill and intangible assets; restructuring risk; potential violations of anti-corruption and anti-bribery laws; risks related to the company's dependence on third parties; downgrades of the company's credit ratings; competition in the biopharmaceutical services industry; changes in outsourcing trends; regulatory risks; trends in the company's customers’ businesses; the company's ability to keep pace with rapid technological change; risks related to the company's indebtedness; fluctuations in the company's financial results and stock price; and other risk factors set forth in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2019 as updated by the company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, and other SEC filings, copies of which are available free of charge on the SEC website at www.sec.gov. The company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.
|Senior Vice President, Investor Relations||Vice President,
|+1 919 745 2745||+1 202 210 5992|
Source: Syneos Health, Inc.